Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

被引：7

作者：

Touzeau, Cyrille ^{[1
]}

Perrot, Aurore ^{[2
]}

Hulin, Cyrille ^{[3
]}

Manier, Salomon ^{[4
]}

Macro, Margaret ^{[5
]}

Chretien, Marie-Lorraine ^{[6
]}

Karlin, Lionel ^{[7
]}

Decaux, Olivier ^{[8
]}

Jacquet, Caroline ^{[9
]}

Tiab, Mourad ^{[10
]}

Leleu, Xavier ^{[11
]}

Corre, Jill ^{[12
]}

Jobert, Alexandra ^{[13
]}

Planche, Lucie ^{[14
]}

Avet-Loiseau, Herve ^{[15
]}

Moreau, Philippe ^{[16
]}

机构：

[1] Ctr Hosp Univ Nantes, Nantes, France

[2] CRCT, Toulouse, France

[3] Ctr Hosp Univ Bordeaux, Pessac, France

[4] Ctr Hosp Univ Hop Huriez, Lille, France

[5] Hop Cote Nacre, Caen, France

[6] CHU Dijon, Dijon, France

[7] CH Lyon Sud, Pierre Benite, France

[8] Ctr Hosp Univ Rennes Hop Pontchaillou, Rennes, France

[9] CHU Nancy, Vandoeuvre Les Nancy, France

[10] Ctr Hosp Dept, La Roche Sur Yon 9, France

[11] Serv Dhematol & Therapie Cellulaire, Poitiers, France

[12] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[13] Ctr Hosp Univ, Nantes, France

[14] CHU Nantes, Nantes, France

[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[16] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174044

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S25 - S25
[2] Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Caillot, Denis
Karlin, Lionel
Decaux, Olivier
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Planche, Lucie
Avet-Loiseau, Herve
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Daratumumab, carfilzomib, fi lzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma
Touzeau, Cyrille
Perrot, Aurore
Hulin, Cyrille
Manier, Salomon
Macro, Margaret
Chretien, Marie-Lorraine
Karlin, Lionel
Escoffre, Martine
Jacquet, Caroline
Tiab, Mourad
Leleu, Xavier
Avet-Loiseau, Herve
Jobert, Alexandra
Planche, Lucie
Corre, Jill
Moreau, Philippe
BLOOD, 2024, 143 (20) : 2029 - 2036
[4] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Derman, Ben A.
Major, Ajay
Rosenblatt, Jacalyn
Avigan, David
Rampurwala, Murtuza M.
Alcantar, Luis
Libao, Bernadette M.
McIver, Amanda
Andreatos, Evangelia
Major, Sarah
Wolfe, Brittany
Gorski, Martha
Karrison, Theodore G.
Stefka, Andrew
Jakubowiak, Andrzej
BLOOD, 2021, 138
[5] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Derman, Benjamin A.
Cooperrider, Jennifer
Rosenblatt, Jacalyn
Avigan, David E.
Rampurwala, Murtuza
Barnidge, David
Major, Ajay
Karrison, Theodore
Jiang, Ken
Ramsland, Aubrianna
Kubicki, Tadeusz
Jakubowiak, Andrzej J.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[6] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Korde, Neha
Derkach, Andriy
Hultcrantz, Malin
Maclachlan, Kylee H.
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Lesokhin, Alexander
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Hofmeister, Craig C.
Kaufman, Jonathan L.
Nooka, Ajay K.
Usmani, Saad Z.
Lonial, Sagar
Joseph, Nisha S.
BLOOD, 2023, 142
[7] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
Bhutani, Manisha
Robinson, Myra
Foureau, David
Atrash, Shebli
Paul, Barry
Guo, Fei
Grayson, Jason M.
Ivanina-Foureau, Anna
Pineda-Roman, Mauricio
Varga, Cindy
Friend, Reed
Ferreri, Christopher J.
Begic, Xhevahire
Norek, Sarah
Drennan, Tiffany
Anderson, Michelle B.
Symanowski, James T.
Voorhees, Peter M.
Usmani, Saad Z.
BLOOD ADVANCES, 2025, 9 (03) : 507 - 519
[8] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, Lisa B.
Tichy, Diana
Besemer, Britta
Haenel, Mathias
Raab, Marc S.
Mann, Christoph
Munder, Markus
Reinhardt, Hans Christian
Nogai, Axel
Goerner, Martin
Ko, Yon-Dschun
de Wit, Maike
Salwender, Hans
Scheid, Christof
Graeven, Ullrich
Peceny, Rudolf
Staib, Peter
Dieing, Annette
Einsele, Hermann
Jauch, Anna
Hundemer, Michael
Zago, Manola
Pozek, Ema
Benner, Axel
Bokemeyer, Carsten
Goldschmidt, Hartmut
Weisel, Katja C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 26 - +
[9] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
Tan, Carlyn
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Patel, Dhwani
Maclachlan, Kylee H.
Lahoud, Oscar B.
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander M.
Korde, Neha
Usmani, Saad
BLOOD, 2022, 140 : 1817 - 1819
[10] Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
Roussel, Murielle
Lauwers-Cances, Valerie
Wuilleme, Soraya
Belhadj, Karim
Manier, Salomon
Garderet, Laurent
Escoffre-Barbe, Martine
Mariette, Clara
Benboubker, Lotfi
Caillot, Denis
Sonntag, Cecile
Touzeau, Cyrille
Dupuis, Jehan
Moreau, Philippe
Leleu, Xavier
Facon, Thierry
Hebraud, Benjamin
Corre, Jill
Attal, Michel
BLOOD, 2021, 138 (02) : 113 - 121

← 1 2 3 4 5 →